{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:12:55Z","timestamp":1778721175222,"version":"3.51.4"},"reference-count":53,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T00:00:00Z","timestamp":1586476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>To date, no head-to-head trials have compared the efficacy of brigatinib and alectinib against anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p), ALK-inhibitor-na\u00efve, advanced non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. We conducted an indirect treatment comparison (ITC) between brigatinib and alectinib, with crizotinib as a common comparator, using a Bayesian model with non-informative prior distribution and assessed the between-study heterogeneity of the studies. The primary efficacy endpoint was progression-free survival (PFS), and efficacy was ranked using the surface under the cumulative ranking (SUCRA) curve values. ITC analysis showed that there were no significant differences in PFS between the brigatinib and alectinib arms. However, the SUCRA values revealed that alectinib ranked the highest by efficacy in the overall patient population, whereas brigatinib ranked the highest by efficacy in the CNS metastasis sub-group. Although there were no significant differences in the incidence of G3\u20135 adverse events between the brigatinib and alectinib arms in the overall patient population, the data were deemed insufficient for the CNS metastasis sub-group analysis. This study provides critical information to clinicians regarding the efficacy of brigatinib for ALK-p, ALK-inhibitor-na\u00efve, advanced NSCLC patients, with and without CNS metastasis. Larger randomized, controlled trials are warranted to confirm our results.<\/jats:p>","DOI":"10.3390\/cancers12040942","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T10:41:52Z","timestamp":1586774512000},"page":"942","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis"],"prefix":"10.3390","volume":"12","author":[{"given":"Koichi","family":"Ando","sequence":"first","affiliation":[{"name":"Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaho","family":"Akimoto","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Manabe","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunari","family":"Kishino","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Homma","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sojiro","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6182-6047","authenticated-orcid":false,"given":"Toshimitsu","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Advanced Cancer Translational Research Institute (Formerly, Institute of Molecular Oncology), Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-486X","authenticated-orcid":false,"given":"Akihiko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Ohmori","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Sagara","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.mcna.2018.12.006","article-title":"Lung cancer","volume":"103","author":"Nasim","year":"2019","journal-title":"Med. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.rcl.2018.01.009","article-title":"Staging lung cancer: Metastasis","volume":"56","author":"Shroff","year":"2018","journal-title":"Radiol. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0733-8619(02)00035-X","article-title":"Brain metastases","volume":"21","author":"Lassman","year":"2003","journal-title":"Neurol. Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","article-title":"Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis","volume":"34","author":"Johung","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.rmed.2013.11.020","article-title":"Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma","volume":"108","author":"Kang","year":"2014","journal-title":"Respir. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ejca.2014.02.001","article-title":"Prospective screening for ALK: Clinical features and outcome according to ALK status","volume":"50","author":"Fallet","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","article-title":"Lung Cancer Statistics","volume":"893","author":"Torre","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"35181","DOI":"10.18632\/oncotarget.26073","article-title":"Brain metastases in ALK-positive NSCLC\u2014Time to adjust current treatment algorithms","volume":"9","author":"Griesinger","year":"2018","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3390\/cancers11081074","article-title":"The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis","volume":"11","author":"Ducray","year":"2019","journal-title":"Cancers"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Aubry, A., Galiacy, S., and Allouche, M. (2019). Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides. Cancers, 11.","DOI":"10.3390\/cancers11030275"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., and Ohmori, T. (2018). Receptor Tyrosine Kinase-Targeted Cancer Therapy. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113491"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S1470-2045(15)00013-3","article-title":"Targeting brain metastases in ALK-rearranged non-small-cell lung cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_16","unstructured":"National Comprehensive Cancer Network (2020, March 19). NCCN Clinical Practice Guidelines in oNCOLOGY: Non-Small Cell Lung Cancer 2018 (Version 3.2018). Available online: https:\/\/www.nccn.org."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","article-title":"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant","volume":"19","author":"Sakamoto","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/JTO.0000000000000455","article-title":"Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib","volume":"10","author":"Gainor","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40265-017-0776-3","article-title":"Brigatinib: First global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"v653","DOI":"10.1093\/annonc\/mdz260.108","article-title":"Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)\u2212positive non\u2013small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)","volume":"30","author":"Popat","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","article-title":"The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models","volume":"22","author":"Zhang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J. Clin. Epidemiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/027298902400448920","article-title":"Markov chain Monte Carlo estimation of a multiparameter decision model: Consistency of evidence and the accurate assessment of uncertainty","volume":"22","author":"Ades","year":"2002","journal-title":"Med. Decis. Mak."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., G\u00f8tzsche, P.C., Ioannidis, J.P., Clarke, M., Devereaux, P.J., Kleijnen, J., and Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med., 6.","DOI":"10.2427\/5768"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_32","unstructured":"Higgins, J.P., and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: Inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Mak."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: Heterogeneity\u2014Subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Mak."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med. Decis. Mak."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"943","DOI":"10.18549\/PharmPract.2017.01.943","article-title":"Network meta-analysis: A technique to gather evidence from direct and indirect comparisons","volume":"15","author":"Tonin","year":"2017","journal-title":"Pharm. Pract. (Granada)"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","article-title":"Bayesian meta-analysis of multiple treatment comparisons: An introduction to mixed treatment comparisons","volume":"11","author":"Jansen","year":"2008","journal-title":"Value Health"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1","volume":"14","author":"Jansen","year":"2011","journal-title":"Value Health"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2","volume":"14","author":"Hoaglin","year":"2011","journal-title":"Value Health"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1007\/s12325-019-00938-1","article-title":"Indirect comparison of ropinirole and pramipexole as levodopa adjunctive therapy in advanced Parkinson\u2019s disease: A systematic review and network meta-analysis","volume":"36","author":"Zhao","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.2217\/imt-2019-0113","article-title":"Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: An indirect comparison meta-analysis","volume":"11","author":"Yan","year":"2019","journal-title":"Immunotherapy"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s00535-019-01572-y","article-title":"Systematic review with network meta-analysis: Indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease","volume":"54","author":"Miwa","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e5182","DOI":"10.1136\/bmj.e5182","article-title":"The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: An indirect comparison in a systematic review","volume":"345","author":"Ford","year":"2012","journal-title":"BMJ"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/A:1008820505350","article-title":"Convergence assessment techniques for Markov chain Monte Carlo","volume":"8","author":"Brooks","year":"1998","journal-title":"Stat. Comput."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J. Comput. Graph. Stat."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.21037\/jtd.2019.03.76","article-title":"Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: A meta-analysis","volume":"11","author":"Zhang","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Elliott, J., Bai, Z., Hsieh, S.C., Kelly, S.E., Chen, L., Skidmore, B., Yousef, S., Zheng, C., and Stewart, D.J. (2020). ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229179"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1002\/cam4.1768","article-title":"The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis","volume":"7","author":"Fan","year":"2018","journal-title":"Cancer Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/acs.jmedchem.6b00306","article-title":"Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase","volume":"59","author":"Huang","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2147\/OTT.S109295","article-title":"The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers","volume":"10","author":"Sabari","year":"2017","journal-title":"OncoTargets Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/4\/942\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:17:30Z","timestamp":1760174250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/4\/942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,10]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["cancers12040942"],"URL":"https:\/\/doi.org\/10.3390\/cancers12040942","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,10]]}}}